Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMSC in Steroid-refractory Acute Graft-Versus-Host Disease
NCT06321198Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Open-label, single-arm trial of iMSC in Acute Graft-Versus-Host Disease (aGvHD), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Adverse Events at 180 days. Started Feb 2024; status: recruiting.
02
Drugs
iMSC
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06321198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321198.